AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31452928 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1197
Study 31452928 — intervention group
Group type: EXPERIMENTAL
Intervention: sarilumab 150 mg
Number of subjects: 1197
Study 31452928 — intervention group
Group type: EXPERIMENTAL
Intervention: sarilumab 200 mg
Number of subjects: 1197
Study 30243679 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple needle puncturing (MNP) using an 18 gauge needle with five punctures each time of release.
Number of subjects: 16
Study 30243679 — intervention group
Group type: COMPARATOR
Intervention: Subperiosteal elevation (SE) using a periosteal elevator with an increment depth of 5 mm each time of release.
Number of subjects: 16
Study 28270164 — intervention group
Group type: EXPERIMENTAL
Intervention: pegcantratinib (TRK inhibitor) applied topically for 12 weeks
Number of subjects: 20
Study 28270164 — intervention group
Group type: COMPARATOR
Intervention: placebo applied topically for 12 weeks
Number of subjects: 20
Study 28270164 — intervention group
Group type: EXPERIMENTAL
Intervention: pegcantratinib (TRK inhibitor) applied topically for 4 weeks
Number of subjects: 20
Study 28270164 — intervention group
Group type: EXPERIMENTAL
Intervention: pegcantratinib (TRK inhibitor) and placebo
Number of subjects: 20
Study 25533992 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance-based financing (PBF)
Number of subjects: 0
Study 23806846 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000 IU hCG and standard luteal phase support (LPS)
Number of subjects: 4
Study 23806846 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRHa; 0.2 mg triptorelin) and standard LPS
Number of subjects: 4
Study 23806846 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (0.2 mg triptorelin) and standard LPS
Number of subjects: 4
Study 23806846 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (0.2 mg triptorelin) without LPS
Number of subjects: 4
Study 21649843 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-pharmacist intervention
Number of subjects: 228
Study 21649843 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 228
Study 18303466 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with degenerative lumbar flat back deformity
Number of subjects: 21
Study 18303466 — intervention group
Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 21
Study 16781361 — intervention group
Group type: EXPERIMENTAL
Intervention: eptifibatide/reduced-dose unfractionated heparin
Number of subjects: 567
Study 16781361 — intervention group
Group type: EXPERIMENTAL
Intervention: eptifibatide/reduced-dose enoxaparin
Number of subjects: 567
Study 16781361 — intervention group
Group type: EXPERIMENTAL
Intervention: eptifibatide
Number of subjects: 567
Study 14700389 — intervention group
Group type: EXPERIMENTAL
Intervention: Listener Comfort Scale (9-point scale)
Number of subjects: 25
Study 14700389 — intervention group
Group type: COMPARATOR
Intervention: Speech Naturalness Scale (9-point scale)
Number of subjects: 25
Study 10634368 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone, flutamide, or finasteride (active drugs)
Number of subjects: 40
Study 10634368 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 40
Study 9198827 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicergoline (8 mg i.v. for 5 days, then 30 mg oral for 25 days)
Number of subjects: 121
Study 9198827 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (1200 mg i.v. for 5 days, then 800 mg oral for 25 days)
Number of subjects: 121
Study 9198827 — intervention group
Group type: COMPARATOR
Intervention: Typical treatment
Number of subjects: 121
Study 8497681 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms salbutamol inhaled 10 min before sBPT (treatment A)
Number of subjects: 8
Study 8497681 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms salbutamol inhaled 2 h before sBPT (treatment B)
Number of subjects: 8
Study 8497681 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhalation 10 min before sBPT (treatment A)
Number of subjects: 8
Study 8497681 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhalation 2 h before sBPT (treatment B)
Number of subjects: 8
Study 3518726 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine in association with digitalis and diuretics (10 patients, Group 1)
Number of subjects: 18
Study 3518726 — intervention group
Group type: COMPARATOR
Intervention: Digitalis and diuretics (8 patients, Group 2)
Number of subjects: 18
Study 29406465 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin (7 mg/kg for 12-17 years, 9 mg/kg for 7-11 years, 12 mg/kg for 1-6 years)
Number of subjects: 82
Study 29406465 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC; primarily vancomycin or cefazolin)
Number of subjects: 82
Study 29406465 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin
Number of subjects: 82
Study 29406465 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC)
Number of subjects: 82
Study 27124034 — intervention group
Group type: EXPERIMENTAL
Intervention: Awake group (LMA removed while following verbal instructions)
Number of subjects: 124
Study 27124034 — intervention group
Group type: COMPARATOR
Intervention: Deep group (LMA removed under deep anesthesia with propofol at 2 μg/mL)
Number of subjects: 124
Study 27124034 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 124
Study 25909612 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia with propofol sedation and pre‐emptive analgesia with ketorolac
Number of subjects: 76
Study 25909612 — intervention group
Group type: COMPARATOR
Intervention: Local anesthesia only
Number of subjects: 76
Study 22276745 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate salvage therapy (no-ARDFP group)
Number of subjects: 283
Study 22276745 — intervention group
Group type: EXPERIMENTAL
Intervention: ARV drug-free period (ARDFP)
Number of subjects: 283
Study 19625976 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3) ingestion at a dosage of 0.3 g.kg(‐1) body weight (BW)
Number of subjects: 10
Study 19625976 — intervention group
Group type: COMPARATOR
Intervention: NaCl placebo (PLAC) at a dosage of 0.045 g.kg(‐1) BW
Number of subjects: 10
Study 19050545 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A treatment
Number of subjects: 23
Study 19050545 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A combined with other treatment modalities
Number of subjects: 23
Study 19050545 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A treatment across multiple facial areas
Number of subjects: 23
Study 15857066 — intervention group
Group type: EXPERIMENTAL
Intervention: ePTFE titanium reinforced membranes
Number of subjects: 40
Study 15857066 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (bioabsorbable membranes with a bone replacement graft)
Number of subjects: 40
Study 15857066 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioabsorbable barriers
Number of subjects: 40
Study 15857066 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative
Number of subjects: 40
Study 12431890 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational outreach intervention (15 practice visits over 21 months)
Number of subjects: 124
Study 12431890 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 124
Study 10440429 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg once daily
Number of subjects: 19185
Study 10440429 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (active control)
Number of subjects: 19185
Study 8634163 — intervention group
Group type: EXPERIMENTAL
Intervention: Castable glass ceramic crowns (Dicor)
Number of subjects: 101
Study 2014712 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg nicergoline once daily
Number of subjects: 30
Study 2014712 — intervention group
Group type: COMPARATOR
Intervention: 4.5 mg co-dergocrine mesilate once daily
Number of subjects: 30
Study 373642 — intervention group
Group type: EXPERIMENTAL
Intervention: Family psychotherapy (6 hours over 4 months)
Number of subjects: 2
Study 373642 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment
Number of subjects: 2
Study 31980515 — intervention group
Group type: EXPERIMENTAL
Intervention: CM-DBS (centromedian thalamic nucleus deep brain stimulation)
Number of subjects: 19
Study 31980515 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative MERs (microelectrode recordings)
Number of subjects: 19
Study 31980515 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting-state fMRI connectivity
Number of subjects: 19
Study 31856887 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily nebulised hypertonic saline (HTS 6%)
Number of subjects: 0
Study 31856887 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbocisteine (750 mg three times per day until visit 3, reducing to 750 mg twice per day)
Number of subjects: 0
Study 31856887 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of twice-daily nebulised HTS and carbocisteine
Number of subjects: 0
Study 31856887 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 28183443 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet rich in n-6PUFA
Number of subjects: 26
Study 28183443 — intervention group
Group type: COMPARATOR
Intervention: Diet rich in saturated fatty acids (SFA)
Number of subjects: 26
Study 25967269 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated HIV services in ANC clinics
Number of subjects: 1172
Study 25967269 — intervention group
Group type: COMPARATOR
Intervention: Nonintegrated PMTCT services
Number of subjects: 1172
Study 24039715 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin
Number of subjects: 15
Study 24039715 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 15
Study 17631079 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm control (attempting to maintain sinus rhythm, principally with antiarrhythmic drugs)
Number of subjects: 3032
Study 17631079 — intervention group
Group type: COMPARATOR
Intervention: Rate control (allowing AF to persist or recur while controlling the ventricular rate)
Number of subjects: 3032
Study 14724486 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite cement
Number of subjects: 8
Study 14724486 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyapatite granules
Number of subjects: 8
Study 11057794 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (500 mg) administered intravenously every 12 hrs
Number of subjects: 5
Study 9493076 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose growth hormone (GH) treatment, daily s.c. dose of either 0.2 or 0.3 IU/kg for 2 years
Number of subjects: 17
Study 9493076 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose growth hormone (GH) treatment
Number of subjects: 17
Study 8366456 — intervention group
Group type: EXPERIMENTAL
Intervention: Centric relation mandibular muscle relaxation appliance (MRA)
Number of subjects: 12
Study 8366456 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular orthotic
Number of subjects: 12
Study 8366456 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cotton rolls)
Number of subjects: 12
Study 3531567 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime suppository (CZX‐S), 250 mg, four times daily for 7 days
Number of subjects: 67
Study 3531567 — intervention group
Group type: COMPARATOR
Intervention: Ceftizoxime intravenous injection (CZX), 60 mg/kg body weight, four times daily for 7 days
Number of subjects: 67
Study 3531567 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime suppository (CZX‐S)
Number of subjects: 67
Study 3531567 — intervention group
Group type: COMPARATOR
Intervention: Ceftizoxime intravenous injection (CZX)
Number of subjects: 67
Study 30926753 — intervention group
Group type: EXPERIMENTAL
Intervention: ebikes
Number of subjects: 14828
Study 30926753 — intervention group
Group type: COMPARATOR
Intervention: bicycles
Number of subjects: 14828
Study 30926753 — intervention group
Group type: EXPERIMENTAL
Intervention: ebike drivers
Number of subjects: 14828
Study 30926753 — intervention group
Group type: EXPERIMENTAL
Intervention: ebike passengers
Number of subjects: 14828
Study 30926753 — intervention group
Group type: EXPERIMENTAL
Intervention: commercial ebikes
Number of subjects: 14828
Study 30926753 — intervention group
Group type: COMPARATOR
Intervention: ebikes vs bicycles
Number of subjects: 14828
Study 30926753 — intervention group
Group type: COMPARATOR
Intervention: males vs females
Number of subjects: 14828
Study 30926753 — intervention group
Group type: COMPARATOR
Intervention: clear weather vs cloudy, rainy and snowy
Number of subjects: 14828
Study 30926753 — intervention group
Group type: COMPARATOR
Intervention: helmet users vs nonusers
Number of subjects: 14828
Study 30289435 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-2048 (30 mg) and vicriviroc (VCV, 182 mg) vaginal rings used continuously for 28 days
Number of subjects: 48
Study 30289435 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-2048 and vicriviroc vaginal rings
Number of subjects: 48
Study 30289435 — intervention group
Group type: COMPARATOR
Intervention: Placebo vaginal rings
Number of subjects: 48
Study 30022409 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-family agenda setting intervention (self-administered paper-pencil checklist)
Number of subjects: 93
Study 26184078 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg melatonin
Number of subjects: 12
Study 26184078 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg melatonin
Number of subjects: 12
Study 26184078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 24193954 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (Cholecalciferol) 60,000 IU per month for 6 months
Number of subjects: 100
Study 22348831 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% L-menthol (n = 32)
Number of subjects: 131
Study 22348831 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8% L-menthol (n = 35)
Number of subjects: 131
Study 22348831 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6% L-menthol (n = 30)
Number of subjects: 131
Study 22348831 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 34)
Number of subjects: 131
Study 19726907 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional program including a feeding protocol and feeding flow
Number of subjects: 38
Study 19726907 — intervention group
Group type: COMPARATOR
Intervention: Usual feeding care (control group)
Number of subjects: 38
Study 17786418 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydrocodeine 60 mg
Number of subjects: 9
Study 15261923 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon angioplasty
Number of subjects: 1301
Study 15261923 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon angioplasty + abciximab
Number of subjects: 1301
Study 15261923 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 1301
Study 15261923 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting + abciximab
Number of subjects: 1301
Study 15261923 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis In Myocardial Infarction flow grade 3 restoration
Number of subjects: 1301
Study 12486341 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive prone extensions of the back
Number of subjects: 249
Study 12486341 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 249
Study 9473085 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleus 22 and Med-El Combi 40 cochlear implants
Number of subjects: 17
Study 9473085 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation with sound field broad-band 80-dB noise
Number of subjects: 17
Study 7637722 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 97
Study 2474103 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary sodium restriction
Number of subjects: 0
Study 2474103 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme (ACE) inhibitors
Number of subjects: 0
Study 2474103 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of dietary sodium restriction and ACE inhibitors
Number of subjects: 0
Study 2474103 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of a thiazide diuretic
Number of subjects: 0
Study 320712 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with factor VIII or factor IX concentrate and a reducing dose of prednisolone
Number of subjects: 30
Study 320712 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 30
Study 30058460 — intervention group
Group type: EXPERIMENTAL
Intervention: Montmorency cherry concentrate (MC)
Number of subjects: 20
Study 30058460 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 20
Study 28753698 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy plus large-balloon dilation (ES-LBD)
Number of subjects: 150
Study 28753698 — intervention group
Group type: COMPARATOR
Intervention: Conventional endoscopic sphincterotomy (without balloon dilation)
Number of subjects: 150
Study 26333778 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard antimicrobial therapy plus daily granulocyte transfusions from donors stimulated with G-CSF and dexamethasone
Number of subjects: 114
Study 26333778 — intervention group
Group type: COMPARATOR
Intervention: Standard antimicrobial therapy
Number of subjects: 114
Study 23294689 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental counterstrain OMT
Number of subjects: 240
Study 23294689 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 240
Study 21608218 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro‐needling at acupoints of the yangming meridian
Number of subjects: 58
Study 21608218 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapies (Control group)
Number of subjects: 58
Study 19472910 — intervention group
Group type: EXPERIMENTAL
Intervention: Thulium laser (Th group)
Number of subjects: 98
Study 19472910 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Ho and Th)
Number of subjects: 98
Study 17454132 — intervention group
Group type: EXPERIMENTAL
Intervention: Legume enriched diet (4 days/week servings)
Number of subjects: 30
Study 17454132 — intervention group
Group type: COMPARATOR
Intervention: Control diet (CD)
Number of subjects: 30
Study 15083284 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab (3 mg/kg or 6 mg/kg)
Number of subjects: 213
Study 15083284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study 11313245 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic peripheral blood hematopoietic stem cell transplantation (PBHSCT)
Number of subjects: 49
Study 11313245 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow hematopoietic stem cell transplantation (BMHSCT)
Number of subjects: 49
Study 11313245 — intervention group
Group type: EXPERIMENTAL
Intervention: PBHSCT with minor ABO mismatch
Number of subjects: 49
Study 11313245 — intervention group
Group type: EXPERIMENTAL
Intervention: PBHSCT without minor ABO mismatch
Number of subjects: 49
Study 11313245 — intervention group
Group type: COMPARATOR
Intervention: BMHSCT with minor ABO mismatch
Number of subjects: 49
Study 11313245 — intervention group
Group type: COMPARATOR
Intervention: BMHSCT without minor ABO mismatch
Number of subjects: 49
Study 11313245 — intervention group
Group type: EXPERIMENTAL
Intervention: PBHSCT
Number of subjects: 49
Study 11313245 — intervention group
Group type: COMPARATOR
Intervention: BMHSCT
Number of subjects: 49
Study 9453087 — intervention group
Group type: EXPERIMENTAL
Intervention: SACH prosthetic mechanism
Number of subjects: 8
Study 9453087 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic prosthetic mechanism
Number of subjects: 8
Study 9453087 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-axis prosthetic mechanism
Number of subjects: 8
Study 9453087 — intervention group
Group type: EXPERIMENTAL
Intervention: Greissinger prosthetic mechanism
Number of subjects: 8
Study 7948819 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched-chain amino acid solution (Aminoleban), intravenous infusion for 3 hours
Number of subjects: 6
Study 3373659 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem hydrochloride
Number of subjects: 15
Study 3373659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 29274894 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based walking program with tailored step-count goals
Number of subjects: 0
Study 29274894 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling to promote walking
Number of subjects: 0
Study 29274894 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of telephone counseling with the internet-based walking program
Number of subjects: 0
Study 29274894 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 0
Study 27528177 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 550 mg 3 times daily for 2 weeks
Number of subjects: 636
Study 27528177 — intervention group
Group type: COMPARATOR
Intervention: Placebo 3 times daily for 2 weeks
Number of subjects: 636
Study 24633376 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing aids
Number of subjects: 102
Study 24633376 — intervention group
Group type: COMPARATOR
Intervention: Headphones
Number of subjects: 102
Study 23423920 — intervention group
Group type: EXPERIMENTAL
Intervention: Coregistered MRI-PET
Number of subjects: 263
Study 23423920 — intervention group
Group type: COMPARATOR
Intervention: PET-CT plus brain MRI
Number of subjects: 263
Study 19108789 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (T4 Montpellier 100)
Number of subjects: 24
Study 19108789 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (Synthroid)
Number of subjects: 24
Study 19108789 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (T4 Montpellier 100) with baseline adjustment
Number of subjects: 24
Study 19108789 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (Synthroid) with baseline adjustment
Number of subjects: 24
Study 15996609 — intervention group
Group type: COMPARATOR
Intervention: Heat wrap therapy alone (n=25)
Number of subjects: 100